

Brain age from the electroencephalogram of sleep



Haoqi Sun^a, Luis Paixao^a, Jefferson T. Oliva^{a,b}, Balaji Goparaju^a, Diego Z. Carvalho^a, Kicky G. van Leeuwen^{a,c}, Oluwaseun Akeju^d, Robert J. Thomas^e, Sydney S. Cash^a, Matt T. Bianchi^{a,1}, M. Brandon Westover^{a,*,1}

^a Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

^b Bioinspired Computing Laboratory, Computer Science Department, University of São Paulo, Brazil

^c University of Twente, Enschede, the Netherlands

^d Department of Anesthesiology, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA

^e Department of Medicine, Division of Pulmonary, Critical Care & Sleep, Beth Israel Deaconess Medical Center, Boston, MA, USA

ARTICLE INFO

Article history:

Received 24 January 2018

Received in revised form 12 October 2018

Accepted 14 October 2018

Available online 19 October 2018

Keywords:

Brain age

Sleep

EEG

Machine learning

ABSTRACT

The human electroencephalogram (EEG) of sleep undergoes profound changes with age. These changes can be conceptualized as “brain age (BA),” which can be compared to chronological age to reflect the degree of deviation from normal aging. Here, we develop an interpretable machine learning model to predict BA based on 2 large sleep EEG data sets: the Massachusetts General Hospital (MGH) sleep lab data set (N = 2532; ages 18–80); and the Sleep Heart Health Study (SHHS, N = 1974; ages 40–80). The model obtains a mean absolute deviation of 7.6 years between BA and chronological age (CA) in healthy participants in the MGH data set. As validation, a subset of SHHS containing longitudinal EEGs 5.2 years apart shows an average of 5.4 years increase in BA. Participants with significant neurological or psychiatric disease exhibit a mean excess BA, or “brain age index” (BAI = BA-CA) of 4 years relative to healthy controls. Participants with hypertension and diabetes have a mean excess BA of 3.5 years. The findings raise the prospect of using the sleep EEG as a potential biomarker for healthy brain aging.

© 2018 Elsevier Inc. All rights reserved.

1. Introduction

Human sleep undergoes robust and predictable changes with age, reflected in both overall sleep architecture and electroencephalogram (EEG) oscillations/waveforms. At the level of sleep architecture (macrostructure), older participants sleep earlier and wake earlier, have shorter sleep duration, increased sleep fragmentation, and reduced percentages of rapid eye movement sleep, as well as (at least in males) deep non-rapid eye movement sleep (Mander et al., 2017; Scullin, 2017). At the level of EEG microstructure, older participants exhibit reduced slow waves during deep sleep (Carrier et al., 2001; Larsen et al., 1995); decreased sleep spindle amplitude, density, and duration (Purcell et al., 2017); and less phase coupling between slow oscillations and sleep spindles (Helfrich et al., 2017). However, no study has yet addressed the inverse problem: how accurately can a person's age be predicted from the sleep EEG? What factors make a person's “BA” older or younger than their chronological age (CA)?

* Corresponding author at: Department of Neurology Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114. Tel.: +1 650-862-1154; fax: +1 617-726-3311.

E-mail address: mwestover@mgm.harvard.edu (M.B. Westover).

¹ These authors contributed equally to the work as co-senior authors.

BA serves as a potential aging biomarker where the variation of BA between individuals of the same chronological age may carry important information about the risk of cognitive impairment, neurological or psychiatric disease, or death. Various biomarkers of aging have been proposed to better predict lifespan and functional capability, ranging from molecular and cellular levels to structural level biomarkers. At the molecular and cellular level, aging-related biomarkers include leukocyte telomere length (Kruk et al., 1995), Ink4/Arf locus expression (Krishnamurthy et al., 2004), N-glycan profile (Vanhooren et al., 2010), mitochondrial DNA deletions (Eshaghian et al., 2006), and DNA-methylation status at CpG sites across the genome (Petkovich et al., 2017) among others. At the structural level, brain anatomy changes dramatically throughout life (Raz and Rodrigue, 2006). For example, cortical volume (Cole et al., 2017), thalamic volume (Redline et al., 2004), and white matter integrity (Mander et al., 2017), each decreases with aging. Using magnetic resonance images (MRI), chronological age can be predicted with mean absolute deviation (MAD) of 5 years in healthy participants (Franke et al., 2010). Various diseases, including Alzheimer's disease, schizophrenia, epilepsy, traumatic brain injury, bipolar disorder, major depression, cognitive impairment, diabetes mellitus, and HIV, are associated with excess BA, that is, older MRI BA than chronological age (Cole, 2017; Cole et al., 2018; Cole and Franke, 2017; Franke et al., 2010, 2012).

Alongside these biomarkers, EEG-based BA is a complement with several potential advantages: (1) EEG-based BA could reflect functional changes rather than structural changes; (2) EEG is more participant friendly, has less costs and contraindications, and in principle could be measured by home-based devices; (3) EEG-based BA could facilitate repeated within-participant measures to assess the effectiveness of interventions, such as medications (Roehrs and Roth, 2010) or brain stimulation (Tasali et al., 2008) that aim to preserve and/or improve brain function and lifespan.

Here, we describe an EEG-based BA and “brain age index” (BAI), that is, the difference between BA and chronological age, developed using 2 large sleep EEG data sets: the Massachusetts General Hospital (MGH) sleep lab data set (Biswal et al., 2017; Sun et al., 2017) and the Sleep Heart Health Study (SHHS) (Dean et al., 2016; Quan et al., 1997; Redline et al., 1998). We identify participants with significant neurological or psychiatric disease in the MGH data set and train the model only on EEGs from participants without these diseases. The effects of different EEG electrode choices are also investigated. The model is then validated on a longitudinal cohort from a subset of the SHHS data set without neurological or cardiovascular disease. We correlate the mean deviation of BA from chronological age with clinical covariates and diseases. Finally, to interpret the BAI, we derive a model-based age norm, which can be compared to show how EEG features contribute to BAI.

2. Material and methods

2.1. Data set

The Partners Institutional Review Board approved retrospective analysis of the deidentified polysomnogram (PSG) data set, acquired in MGH between 2008 and 2012, without requiring additional consent for its use in this study. The EEG signals contain 6 channels: frontal (F3-M2 and F4-M1), central (C3-M2 and C4-M1), and occipital (O1-M2 and O2-M1), each referenced to the contralateral mastoid. EEG signals are sampled at 200 Hz. The signals are segmented into nonoverlapping 30-second epochs. Each PSG is scored by 1 of 7 EEG technicians according to the American Academy of Sleep Medicine (AASM) standards (AASM, 2007). Epochs are scored as 1 of 5 stages: wake (W), rapid eye movement, Non-REM stage 1 (N1), Non-REM stage 2 (N2), and Non-REM stage 3 (N3). The inclusion criteria include participants (1) age between 18 to 80 years; (2) who underwent diagnostic PSG (not split night study); and (3) with a clinical diagnosis available from 5 years before to 1 year after the PSG recording from the hospital database. To remove the potentially confounding effect of imputing missing sleep stages, we exclude EEGs with missing sleep stages and investigate their effect on the BA in the supplementary material (Figure S1).

We define a participant as “having significant neurological or psychiatric disease” if they have at least 1 neurological or psychiatric diagnosis in Table S1 (Supplementary Material) in the medical record from 5 years before to 1 year after the PSG recording. This definition is similar to those used in prior studies of MRI BA, for example, Brain Images of Normal Participants (BRAIN) (Job et al., 2017) and Open Access Series of Imaging Studies (OASIS) (Marcus et al., 2010), (Steffener et al., 2016) and (Cole et al., 2015). Although some evidence suggests sleep apnea may be a risk factor for dementia, the relationship remains uncertain (Ding et al., 2016). We therefore do not exclude participants with sleep apnea. However, we compare BAIs for participants without sleep apnea (apnea-hypopnea index [AHI] < 5) versus those with moderate to severe apnea (AHI > 15) using a *t*-test. We refer to participants without significant neurological or psychiatric disease as “healthy.”

In total, we identify 2532 participants, 167 of whom have significant neurological or psychiatric diseases. Table 1 provides

Table 1
MGH sleep data set summary

Characteristics	Value
Number of EEGs	2532 (including 167 with significant neurological or psychiatric disease ^a)
Age (year), median (IQR)	50 (38–61)
Gender	Female 1266 (50%), Male 1266 (50%)
BMI (kg/m ²), median (IQR)	29 (25–34)
Overall AHI (per hour), median (IQR)	5 (2–12)
Normal (<5)	1232 (48.7%)
Mild sleep apnea (5 ≤ AHI < 15)	813 (32.1%)
Moderate sleep apnea (15 ≤ AHI < 30)	373 (14.7%)
Severe sleep apnea (AHI ≥ 30)	114 (4.5%)

Key: IQR, interquartile range; BMI, body mass index; AHI, apnea-hypopnea index (# apnea events per hour of sleep) at 4% oxygen desaturation for hypopnea.

^a See Table S1 in the supplementary material.

summary statistics for the data set. Self-reported medication intake collected at the time of PSG recording is reported in Supplemental Table S2.

We also use a subset of the SHHS data set (Dean et al., 2016; Quan et al., 1997; Redline et al., 1998), which contains repeated EEGs from the same participant in two visits about 5 years apart, making it possible to evaluate the longitudinal reliability of our model at the population level. The participant inclusion criteria are (1) having EEGs from both visits; (2) chronological age between 40 and 80 years at both visits (minimum age in SHHS is 40); (3) having EEG and sleep stage scoring of high quality according to SHHS specifications (Table S3); and (4) having no neurological or cardiovascular disease (Table S3). We also exclude EEGs with missing sleep stages. As a result, 987 EEGs from SHHS visit 1 and 987 paired EEGs from visit 2 are used. The average difference in the chronological age between the 2 visits is 5.2 years. Unlike the MGH data set, the SHHS data set uses 2 EEG channels (C3-M2 and C4-M1) and is scored according to R&K standard (Rechtschaffen, 1968). To make scoring consistent across data sets, we combine S3 and S4 in SHHS to match the scoring of N3 in the MGH data. Summary statistics for the SHHS data set are shown in Table 2.

2.2. EEG preprocessing and artifact removal

EEG signals are notch-filtered at 60 Hz to reduce line noise, and bandpass filtered from 0.5 Hz to 20 Hz to reduce myogenic artifacts. For 30s-epochs, those with absolute amplitude larger than 500 μ V are removed to minimize movement artifacts. Epochs containing flat EEG for more than 2 seconds are also removed. We also exclude EEGs contaminated by electrocardiogram, indicated by 1 Hz harmonic in the EEG spectrogram. To reduce interparticipant variance,

Table 2
Sleep heart health study data set summary

Characteristics	SHHS visit 1 (SHHS1)	SHHS visit 2 (SHHS2)
Number of EEGs	987	987 (same participants as SHHS1)
Age (year), median (IQR)	58 (53–66)	64 (58–71)
Gender	Female 609 (62%), Male 378 (38%)	
BMI (kg/m ²), median (IQR)	27 (25–30)	28 (25–31)
Overall AHI (per hour), median (IQR)	3 (1–7)	5 (2–11)

the amplitude of each EEG channel is normalized to have zero median and unit interquartile range across the whole night. The total amount of data removed by these preprocessing procedures is 7% in the MGH data set and 9% in the SHHS data set.

2.3. Feature extraction

For age prediction, we extract features from sleep EEG used in sleep staging in our previous work (Sun et al., 2017). We extract 102 features from each 30-second epoch covering both time and frequency domains, as summarized in Table S4. For each EEG recording, we average the features in each of the 5 sleep stages over time, yielding $102 \times 5 = 510$ features per EEG. The features are log-transformed to render feature distributions approximately Gaussian. Subsequently, these features are z-transformed to have zero mean and unit standard deviation in the training set. The same z-transformation is applied to the testing set.

2.4. Brain age prediction

The model minimizes an objective function $J(w, b)$ with two terms: (1) mean squared prediction error; and (2) magnitude of the covariance between CA and BAI:

$$J(w, b) = BAI^2 + \lambda |Cov(CA, BAI)|$$

where $BA_i = \text{softplus}(w^T x_i + b) = \ln[1 + e^{w^T x_i + b}]$, that is, a linear combination of EEG features followed by a softplus function to ensure positivity of BA; $BAI^2 = \sum_{i=1}^N (BA_i)^2 / N = \sum_{i=1}^N (BA_i - CA_i)^2 / N$ is the mean squared prediction error; and $Cov(CA, BAI) = \sum_{i=1}^N (CA_i - CA)(BA_i - BAI)$ is the average absolute correlation (covariance) between the chronological age CA_i and brain age index BAI_i . Minimizing the first term BAI^2 encourages the model to produce predictions BA that are accurate (close to CA). Minimizing the second component $Cov(CA, BAI)$ encourages deviations of BA from CA to be uncorrelated with CA. The second

component is weighted by a hyperparameter λ , which tradeoff between the 2 components.

To determine the optimal hyperparameter λ , we randomly select 300 EEGs from the training set to serve as internal validation data. We perform grid search on λ ranging from [0, 1, 5, 10]. We find the hyperparameter with the highest performance on the internal validation set. The performance metric for each hyperparameter is evaluated using $\text{corr}(CA, BA) - |\text{corr}(CA, BAI)|$, where $\text{corr}(\cdot)$ denotes Pearson's correlation. A larger $\text{corr}(CA, BA)$ and a smaller $|\text{corr}(CA, BAI)|$ indicate better model performance. Here, the metric is correlation instead of covariance or prediction error because correlation is normalized and comparable among different hyperparameter values. Once the optimal hyperparameter with the best validation performance is determined, the validation set is combined with the rest of the training set, and the model is retrained using the optimal hyperparameter.

We maintain strict separation of training and testing participants to achieve statistically unbiased estimates of model's performance. The reported results are based on the testing set, unless stated.

3. Results

3.1. EEG-based brain age prediction

The MGH data set ($N = 2532$) was partitioned into a healthy training set ($N = 1343$) used to train the model, and a testing set ($N = 1189$) to evaluate model performance. In the testing set, 167 had significant neurological or psychiatric disease (Table S1); the remaining 1022 were healthy. A comparison between these 2 groups is presented in subsection "Correlation between Disease and Brain Age Index".

We first compared age prediction performance using the sleep macrostructure features (Mander et al., 2017; Redline et al., 2004) (30 features, Table S5) versus using the 510 sleep microstructure EEG features, on the testing set. As shown in Fig. 1, the MAD of BA from CA using macrostructure features was much higher (23.3 years) than that using EEG features (7.8 years), and the correlation was weaker (0.46, 95% CI 0.42–0.50) than that using EEG




Fig. 1. Scatter plot of predicted BA versus CA using (A) sleep EEG macrostructure features (described in Table S5) and (B) sleep microstructure features (described in Table S4). The red dashed diagonal line is the identity line where BA is equal to CA. Both plots are obtained from the same testing participants, including both healthy and with significant neurological or psychiatric disease. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)




Fig. 2. Cases in which BA matches (diagonal) or is younger or older than CA (off diagonal). Each panel consists of a hypnogram and the corresponding spectrogram. Spectrograms are calculated as the average across the 6 EEG channels. The horizontal axis is time in hours. The case indicated by * is described in the main text.

features (0.82, 95% CI 0.80–0.84). The results suggest that the effects of age on brain activity are more consistently reflected in sleep EEG (microstructure) than in sleep stage composition (macrostructure). The progression of EEG features with age is further illustrated by a two-dimensional visualization of the feature space in Figure S2.

In Fig. 2, we show spectrograms of sleep EEGs from 6 typical individuals, arranged as a “confusion matrix”, where rows show participants with CA in young (18–30 years), intermediate (40–50 years), and older groups (60–80 years) from top to bottom, and columns with BA in three groups from left to right. The participants positioned along the diagonal line are examples of participants with matched CA and BA. As an example, the middle right panel indicated by * shows a 48-year-old female diagnosed with hypertension, seizure disorder, kidney stone, and arteriosclerotic heart disease, whose predicted BA was 65.8 years ($BAI = BA - CA = 65.8 - 48 = 17.8$ years). One visually apparent abnormality is the relatively weaker sleep spindle density during N2 compared to healthy participants of similar chronological age (middle left and center panels).

3.2. Effect of EEG electrode placement

Most home-based EEG devices use fewer electrodes than lab-based PSG. We therefore explored how EEG-based age prediction depends on the number and location of EEG electrodes. Prediction performance on the 1022 healthy testing participants using

different subsets of EEG electrodes is shown in Table 3. Using all 6 electrodes (2 frontal, 2 central, 2 occipital) provided the lowest prediction error (7.6 years) and the highest correlation with CA (0.83) (Kruskal-Wallis p -value < 0.01). If limited to recording EEG using 2 electrodes only, the frontal electrodes provided the best performance with nonsignificant difference compared to all 6 electrodes (p -value = 0.20); the central and occipital electrodes led to significantly reduced performance (p -value < 0.01). Therefore, it is suggested to use frontal EEG electrodes if required to use fewer EEG electrodes.

3.3. Longitudinal reliability using two central EEG channels

To assess the longitudinal reliability of the brain age model at the population level, we used a subset of the SHHS data set where each participant underwent 2 study visits, referred as SHHS1 and SHHS2. The data set contains 987 adults for a total of 1974 nights of EEG recorded from C3-M2 and C4-M1 only. The average increase of chronological age between the 2 visits was 5.2 years (standard deviation, SD 0.5 years) (Table 2). We trained the model in 2 ways.

First, we trained the model on 752 participants with paired EEGs (1504 EEGs) from both visits and tested on the held out 235 participants with paired EEGs (470 EEGs) in both visits. Testing results are shown in Fig. 3A and B. The MAD was 8.1 years on SHHS1 and 7.8 years on SHHS2. The Pearson’s correlation was 0.66 (95% CI 0.58–0.73) on SHHS1 and 0.67 (95% CI 0.59–0.73) on SHHS2. The average difference in predicted BA between the 2 visits, $\Delta BA = BA_2 - BA_1$, was 5.4 years (SD 9.3 years) (Fig. 3C); hence, the magnitude of the observed difference between the progression of mean chronological age $\Delta CA = CA_2 - CA_1$ and mean BA ΔBA was $|\Delta CA - \Delta BA| = |5.2 - 5.4| = 0.2$ years. A t -test revealed that this difference was not statistically significant (p -value = 0.7).

Second, we investigated the effect of the training population. To do this, we trained the model on the 2365 EEGs from healthy participants in MGH data set using the C3-M2 and C4-M1 leads only (to be consistent with SHHS EEGs). We then predicted BA on the 1974

Table 3
Brain age using subsets of EEG electrodes in healthy testing participants

Electrode	Mean absolute deviation (years)	Pearson’s correlation
Frontal (F3 and F4)	9.6	0.80 (0.77–0.82)
Central (C3 and C4)	12.2	0.78 (0.75–0.80)
Occipital (O1 and O2)	10.0	0.76 (0.73–0.78)
All electrodes	7.6	0.83 (0.81–0.85)




Fig. 3. (A, B) Chronological age (CA) versus Brain age (BA) from the 470 testing EEGs in SHHS when trained on the other part of SHHS. The red dashed line indicates identity. (D, E) CA versus BA from the 1974 testing EEGs in SHHS when trained on the healthy participants in MGH data set. (C, F) Histogram of BA differences between 2 SHHS visits, showing tracking of CA at the population level. The mean difference in predicted BA was 5.4 years in (C); and 4.3 years in (F). The dashed red line is the Gaussian fit to the histogram. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

paired EEGs in SHHS as the testing set. Results on the testing set are shown in Fig. 3D and E. The MAD was 8.2 years on SHHS1 and 9.4 years on SHHS2. The Pearson's correlation was 0.61 (95% CI 0.57–0.65) on SHHS1 and 0.56 (95% CI 0.52–0.60) on SHHS2. The average difference in predicted BA between the 2 visits Δ BA was 4.3 years (SD 9.6 years) (Fig. 3F). In this case the difference between mean progression of chronological age was statistically significant (p -value < 0.01, t -test), indicating that different populations (data sets) did introduce some systematic error. However, the magnitude of this difference was relatively small, $|\Delta$ CA- Δ BA| = $|5.2-4.3|$ = 0.9 years.

The results suggest that, at the population level, the model longitudinally tracked brain aging when trained on either the SHHS or MGH cohorts, with a marginal error of 0.2–0.9 years. We note that these results were obtained using a restricted set of EEG electrodes (C3-M2 and C4-M1). Given limited channels in the SHHS EEG data, we were not able to investigate whether even higher accuracy is possible using a full set of channels.

3.4. Correlation between covariates and brain age index

We collected various covariates from the MGH data set, including sleep macrostructure (i.e., sleep stages), the Epworth Sleepiness Scale, and measures of sleep disruption, and then obtained the Spearman's correlation with BAI. For healthy participants, the covariates with statistically significant (p < 0.05) Spearman's correlation are shown in ascending order in Table 4. The full list of all covariates is shown in Table S6 in the supplementary material. The amount of deep sleep (N3) showed the most negative correlation with BAI, although the correlation is weak. Wake time after sleep onset also showed weak but significant positive correlation with BAI.

One noteworthy lack of association is that BAI is statistically independent of AHI (apnea-hypopnea index; number of apnea events per hour of sleep, used to quantify severity of sleep apnea). A scatter plot between AHI and CA/BA/BAI shown in Figure S3 in the supplementary material reveals a correlation between AHI and CA and BA but not BAI. The histogram of BAI for AHI < 5 and AHI > 15 are shown in Figure S4, showing no significant difference between the 2 groups (t -test, p = 0.70).

The weak correlations in Table 4 indicate that BAI was relatively independent of these covariates. Therefore, BAI can be interpreted as a relatively orthogonal metric for measuring sleep and brain health. In other words, BAI was robust in participants with different characteristics.

3.5. Correlation between disease and brain age index

We next investigated some population-level health correlates of “excess BA”, $BAI = BA - CA > 0$. In Materials and Methods, we describe criteria for significant neurological or psychiatric disease (Table S1), which we hypothesized to have older BA than CA. This hypothesis was verified in Fig. 4A. BAI for the healthy group (2365

Table 4
Covariates that have significant correlation with BAI (BA-CA)

Covariate	Spearman's correlation
N3 time	−0.11
N3 percentage	−0.087
Sleep efficiency	−0.082
Total sleep time	−0.076
N2 time	−0.065
Respiratory disturbance index	0.043
N1 percentage	0.058
Wake time after sleep onset	0.081




Fig. 4. (A) Histograms of BAIs for participants with (red) and without (blue) significant neurological or psychiatric disease defined in Table S1. The dashed lines show the Gaussian fit to these distributions. The difference of group means is 4 years. * p -value = $6.1 \times 10^{-7} < 0.05$. (B) Histograms of BAIs for participants with (red) and without (blue) hypertension and diabetes. The difference of group means is 3.5 years. * p -value = $1.8 \times 10^{-4} < 0.05$. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

participants) was around 0 years, whereas BAI for the group with significant neurological and psychiatric disease (167 participants) increased up to 4 years with a significant difference (t -test p -value < 0.01). Therefore, at the population level, participants with significant neurological or psychiatric disease had on average BA 4 years older than their chronological age. Furthermore, in the healthy group, the MAD was 7.6 years, and correlation between CA and BA was 0.83; while in the group with significant neurological and psychiatric disease, the MAD was larger at 9.5 years and correlation smaller at 0.74.

Although often not associated with any formal neurological or psychiatric diagnosis, there is biological plausibility and accumulating evidence for the idea that hypertension and diabetes mellitus accelerate brain aging (Gorelick et al., 2011, 2017). We therefore explored whether EEG BA is sensitive to hypertension and diabetes. These participants were identified using the diagnosis from 5 years before to 1 year after the PSG recording, as well as the self-reported medication intake form collected at the time of PSG recording. As compared in Fig. 4B, the control group was defined as participants taking no medications, having no diagnoses of hypertension or diabetes, and no significant neurological or psychiatric disease. The control group had a mean excess BA of $BAI = -1.1$ years ($n = 472$). The “contrast” group was defined as participants with both hypertension and diabetes, which had $BAI = 2.4$ years ($n = 137$). The attributable excess BA was 3.5 years ($p = 0.0002$).

3.6. Model-derived age norm

The parametric formulation of our BA model allows studying individual differences at the level of EEG features. To do this, we first derived an “age norm”, that is, typical EEG feature values at different CAs with matched BAs. Specifically, the age norm of age x was obtained by averaging EEG features from all healthy participants who had both CA and BA within $[x-5, x+5]$ years.

The age norm showed that when following a normal aging process, the features most negatively correlated with age were delta band (< 4 Hz) powers in stage N3 sleep in the occipital and central areas; and features that most positively correlate with age were theta band (4–8 Hz) powers in stage N1 sleep in frontal, occipital, and central areas. The details are described in Table S6.

Using this model-derived age norm, we could examine reasons for deviation from CA quantitatively. For example, Fig. 5A shows the EEG spectrogram of a 29-year-old female with multiple medical problems, including diabetes mellitus, obesity, smoking, a cerebrovascular accident, congestive heart failure, and acute renal failure. Her brain activity resembled that of a much older adult. Her BA was 63 years. As shown in Fig. 5B, when compared to the age norm, her sleep EEG exhibited (1) less delta to theta ratio during deep N3 sleep; and (2) less theta and alpha band bursts, that is, more continual theta and alpha, during N2 sleep.

Note that our results only showed that BAI reflects age and pathology at the population level. Nevertheless this example suggested the possibility that BAI may, with further studies, serve as a personalized biomarker of brain health. Other examples are shown in Figures S5–S7 in the supplementary material.

4. Discussion

The concept of differential aging—the idea that a 50-year-old can “have the heart of a 20-year-old” or that the lungs of a 30-year-old smoker “work like they’re 80”—is useful clinically and is gaining scientific traction. Similarly, while cognitive decline is a “normal” part of aging, some individuals clearly age better than others. In this work, we have developed a machine learning model that leverages statistical changes across the adult lifespan in the pattern of brain activity during sleep. We call the predicted age “brain age” or BA. Model predictions are highly correlated with CA ($r = 0.83$, $MAD = 7.6$ years) for healthy participants, and at the population level, the model accurately tracks advancing age. More interestingly, this study presents preliminary evidence that excess BA (EEG BA in excess than chronological age) reflects underlying brain pathology. In particular, our findings show that significant neurological or psychiatric disease accelerate brain aging, as do hypertension and diabetes. These findings suggest that features of brain activity during sleep, reflected in EEG, can be harnessed using machine learning to provide an easily accessible and low-cost biomarker of brain health.

One strength of our study is the use of large data sets: 2532 sleep EEGs from the MGH Sleep Lab, and 1974 sleep EEGs from the SHHS data set (Dean et al., 2016; Quan et al., 1997; Redline et al., 1998).




Fig. 5. (A) The hypnogram and EEG spectrogram from frontal (F), central (C), and occipital (O) channels. (B) The left 2 bars show the chronological age and brain age for this participant. The right parts show the top 5 features that contribute most positively to the older brain age. The blue bar is the feature value based on the model-based age norm at age 29 years, with the error bar indicating the standard deviation. The red bar is the feature value for this participant. The number at the top/bottom indicates the model weight associated with this feature. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

The number of EEGs involved in this study is large among relevant “BA” studies (Cole and Franke, 2017). The large size of the data sets helps to ensure the statistical power as well and to minimize selection bias. A large training set helps ensure that the trained model does not overfit to a particular data set, improving the ability to generalize when applied beyond the training set. A large testing set allows accurate statistical measurement of how accurately the model performs.

Another strength of our study is the use of a parametric model, which improves model interpretation by inspecting each EEG feature and comparing to the age norm for each feature explicitly. In contrast, nonparametric or semiparametric models such as kernel methods and Gaussian process models (Franke et al., 2010) estimate age based on the similarity to the training examples, where the contribution of each feature is involved implicitly. An example of interpretability is demonstrated in Fig. 5.

The deviation of EEG-based BA from CA arises from multiple sources, which can be divided into technical and physiological sources. Potential technical sources include (1) first-night effect, where a participant’s quality of sleep is impaired by the effect of the environment and polysomnographic recording; (2) constraints of the current model, which assumes BA is a linear combination (though approximately due to the softplus function to ensure positivity) of sleep EEG features averaged separately for each sleep stage over the night; and (3) imputation of missing sleep stages based on Figure S1. Neurophysiological sources, our central interest, might arise from (1) night-to-night variability; (2) underlying diagnosed or undiagnosed neurological or psychiatric diseases. For example, sleep pathology enhances amyloidogenesis, implicated in the development of Alzheimer’s dementia (Ju et al., 2014). Moreover, normal glymphatic flow, required for clearance of amyloid and other metabolic wastes that accumulate during wakefulness, requires undisturbed sleep (Benveniste et al., 2017; Hladky and Barrand, 2017); (3) general medical health, including diabetes and cerebrovascular disease; (4) genetically determined inter-individual differences in the EEG; and (5) exposure to environmental insults. Further studies are needed to clarify the relative contributions of the various types of neurophysiological sources and to

measure the association between EEG-based BA and various outcomes, such as cognitive performance (Steffener et al., 2016), intelligence (Ujma et al., 2017), and survival (Cole et al., 2018). Additional unobserved sources, such as diet, exercise, and diseases, might also further explain the variance. An additional important question for future investigation is whether interventions can change the brain aging process and lifespan, and whether improvements in brain health can be effectively tracked using the sleep EEG.

Our study has important limitations. (1) Although we have demonstrated that the change of BA after 5 years of follow-up is close to 5 years at population level, our data set does not allow studying variability in BA at the individual level. Understanding the factors governing changes in BA over time and test-retest reliability at the individual level are important topics for further research. (2) Although we attempted to exclude participants with significant neurological or psychiatric disease (criteria in Tables S1 and S3), it is possible that both the MGH and SHHS data sets still include a variety of health conditions that could affect brain health. Obtaining a large, “truly healthy” cohort is an important future direction that will require a prospectively controlled study. (3) We only include ages 18 to 80 years. The distribution of ages in the data set is not uniform, where most of the participants are at middle age. This could lead to less accurate prediction of BA for older and younger participants. (4) Our model formulation is limited. Advanced algorithms such as convolutional neural networks, trained end-to-end from raw EEG data rather than on hand-engineered physiologically based features as in our model, might predict age and capture biologically important variability more accurately (Biswal et al., 2017; Cole et al., 2017). In addition, whereas we average features within the same sleep stage, representations learned by recurrent neural network models might provide a more powerful summary of the overnight EEG that utilizes more information (e.g., fragmentation of sleep stages due to high AHI) and more accurately reflects BA. (5) Finally, conclusions from our present results are primarily limited to the population level. Although selected cases raise the possibility that BAI is meaningful for individuals. Our data provide no way to definitively

determine the sources of variation at the level of individuals (e.g., biological effects related to brain health vs. random night-to-night variation). This is of course a classic issue in the clinical/biological prediction literature, where evidence for a correlation at a population level does not necessarily translate into a usable algorithm for individual use. Nevertheless, our findings form the basis for further studies and refinements. To reach individual level, first, further studies with more granular detail about individuals' medical conditions (e.g., medication doses), neurological function (e.g., neuropsychiatric test scores), and brain structure (e.g., cortical thickness, total brain volume, white matter integrity, etc.) will be required to better understand the biological mechanism of deviations between EEG-based BA and chronological age.

5. Conclusions

Using a machine learning model, a measure of BA can be inferred from the pattern of brain activity during sleep. Our data suggest that neurological, psychiatric, and medical illnesses that adversely affect brain health result in the model predicting an older BA. Using participants with matched chronological age and BA, we developed an age norm to provide a direct interpretation of an individual's deviation from normal aging in terms of EEG features. In summary, the EEG-based BA serves as a potential biomarker, which sets the stage for future EEG-based studies of brain health.

Disclosure

The authors declare that they have no conflict of interest.

Acknowledgements

MBW reports grants from NIH-NINDS (NIH-NINDS 1K23NS090900, 1R01NS102190, 1R01NS102574, 1R01NS107291). MTB has received funding from the Center for Integration of Medicine and Innovative Technology, the Milton Family Foundation, the MGH-MIT Grand Challenge, and the American Sleep Medicine Foundation, and the Department of Neurology. MTB has had research agreements with MC10 and Insomnisolv, and consulting agreements with McKesson, International Flavors and Fragrances, and Apple Inc., has served as a medical monitor for Pfizer, and has provided expert testimony in sleep medicine. RJT reports the following: (1) Patent, license and royalties from MyCardio, LLC, for an ECG-based method to phenotype sleep quality and sleep apnea; (2) Grant support, license, and intellectual property (patent submitted) from DeVilbiss Healthcare; (3) GLG consulting for general sleep medicine; (4) Intellectual Property (patent) for a device using CO2 for central/complex sleep apnea. This is not an industry supported study, and none of these entities had any role in the study.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.neurobiolaging.2018.10.016>.

References

AASM, 2007. *The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications*. AASM, Westchester.

Benveniste, H., Lee, H., Volkow, N.D., 2017. The glymphatic pathway: waste removal from the CNS via cerebrospinal fluid transport. *Neuroscientist* 23, 454–465.

Biswal, S., Kulas, J., Sun, H., Goparaju, B., Westover, M.B., Bianchi, M.T., Sun, J., 2017. SLEEPNET: Automated Sleep Staging System via Deep Learning arXiv preprint arXiv:1707.08262: Online.

Carrier, J., Land, S., Buysse, D.J., Kupfer, D.J., Monk, T.H., 2001. The effects of age and gender on sleep EEG power spectral density in the middle years of life (ages 20–60 years old). *Psychophysiology* 38, 232–242.

Cole, J.H., 2017. Neuroimaging-derived brain-age: an ageing biomarker? *Aging (Albany, NY)* 9, 1861.

Cole, J.H., Franke, K., 2017. Predicting age using neuroimaging: innovative brain ageing biomarkers. *Trends Neurosci.* 40, 681–690.

Cole, J.H., Leech, R., Sharp, D.J., Initiative, A.S.D.N., 2015. Prediction of brain age suggests accelerated atrophy after traumatic brain injury. *Ann. Neurol.* 77, 571–581.

Cole, J.H., Poudel, R.P., Tsagkrasoulis, D., Caan, M.W., Steves, C., Spector, T.D., Montana, G., 2017. Predicting brain age with deep learning from raw imaging data results in a reliable and heritable biomarker. *NeuroImage* 163, 115–124.

Cole, J., Ritchie, S., Bastin, M., Hernández, M.V., Maniega, S.M., Royle, N., Corley, J., Pattie, A., Harris, S., Zhang, Q., 2018. Brain age predicts mortality. *Mol. Psychiatry* 23, 1385–1392.

Dean, D.A., Goldberger, A.L., Mueller, R., Kim, M., Rueschman, M., Mobley, D., Sahoo, S.S., Jayapandian, C.P., Cui, L., Morrical, M.G., 2016. Scaling up scientific discovery in sleep medicine: the national sleep research resource. *Sleep* 39, 1151–1164.

Ding, X., Kryscio, R.J., Turner, J., Jicha, G.A., Cooper, G., Caban-Holt, A., Schmitt, F.A., Abner, E.L., 2016. Self-reported sleep apnea and dementia risk: findings from the prevention of Alzheimer's disease with vitamin E and selenium trial. *J. Am. Geriatr. Soc.* 64, 2472–2478.

Eshaghian, A., Vleugels, R.A., Canter, J.A., McDonald, M.A., Stasko, T., Sligh, J.E., 2006. Mitochondrial DNA deletions serve as biomarkers of aging in the skin, but are typically absent in nonmelanoma skin cancers. *J. Invest. Dermatol.* 126, 336–344.

Franke, K., Luders, E., May, A., Wilke, M., Gaser, C., 2012. Brain maturation: predicting individual BrainAGE in children and adolescents using structural MRI. *Neuroimage* 63, 1305–1312.

Franke, K., Ziegler, G., Klöppel, S., Gaser, C., Initiative, A.S.D.N., 2010. Estimating the age of healthy subjects from T1-weighted MRI scans using kernel methods: exploring the influence of various parameters. *Neuroimage* 50, 883–892.

Gorelick, P.B., Furie, K.L., Iadecola, C., Smith, E.E., Waddy, S.P., Lloyd-Jones, D.M., Bae, H.-J., Bauman, M.A., Dichgans, M., Duncan, P.W., 2017. Defining optimal brain health in adults: a presidential advisory from the American Heart Association/American Stroke Association. *Stroke* 48, e284–e303.

Gorelick, P.B., Scuteri, A., Black, S.E., DeCarli, C., Greenberg, S.M., Iadecola, C., Launer, L.J., Laurent, S., Lopez, O.L., Nyenhuis, D., 2011. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 42, 2672–2713.

Helfrich, R.F., Mander, B.A., Jagust, W.J., Knight, R.T., Walker, M.P., 2017. Old brains come uncoupled in sleep: slow wave-spindle synchrony, brain atrophy, and forgetting. *Neuron* 97, 221–230.e4.

Hladky, S.B., Barrand, M.A., 2017. Metabolite Clearance During Wakefulness and Sleep. In: Barrett, J.E. (Ed.), *Handbook of Experimental Pharmacology*. Springer, Berlin; Heidelberg.

Job, D.E., Dickie, D.A., Rodriguez, D., Robson, A., Danso, S., Pernet, C., Bastin, M.E., Boardman, J.P., Murray, A.D., Ahearn, T., 2017. A brain imaging repository of normal structural MRI across the life course: brain images of normal subjects (BRAINS). *NeuroImage* 144, 299–304.

Ju, Y.-E.S., Lucey, B.P., Holtzman, D.M., 2014. Sleep and Alzheimer disease pathology—a bidirectional relationship. *Nat. Rev. Neurol.* 10, 115.

Krishnamurthy, J., Torrice, C., Ramsey, M.R., Kovalev, G.I., Al-Regaiey, K., Su, L., Sharpless, N.E., 2004. Ink4a/Arf expression is a biomarker of aging. *J. Clin. Invest.* 114, 1299.

Kruk, P.A., Rampino, N.J., Bohr, V.A., 1995. DNA damage and repair in telomeres: relation to aging. *Proc. Natl. Acad. Sci. U. S. A.* 92, 258–262.

Larsen, L.H., Moe, K.E., Vitiello, M.V., Prinz, P.N., 1995. Age trends in the sleep EEG of healthy older men and women. *J. Sleep Res.* 4, 160–172.

Mander, B.A., Winer, J.R., Walker, M.P., 2017. Sleep and human aging. *Neuron* 94, 19–36.

Marcus, D.S., Fotenos, A.F., Csernansky, J.G., Morris, J.C., Buckner, R.L., 2010. Open access series of imaging studies: longitudinal MRI data in nondemented and demented older adults. *J. Cogn. Neurosci.* 22, 2677–2684.

Petkovich, D.A., Podolskiy, D.I., Lobanov, A.V., Lee, S.-G., Miller, R.A., Gladyshev, V.N., 2017. Using DNA methylation profiling to evaluate biological age and longevity interventions. *Cell Metab.* 25, 954–960.e956.

Purcell, S., Manoach, D., Demanuele, C., Cade, B., Mariani, S., Cox, R., Panagiotaropoulou, G., Saxena, R., Pan, J., Smoller, J., 2017. Characterizing sleep spindles in 11,630 individuals from the national sleep research resource. *Nat. Commun.* 8, ncomms15930.

Quan, S.F., Howard, B.V., Iber, C., Kiley, J.P., Nieto, F.J., O'Connor, G.T., Rapoport, D.M., Redline, S., Robbins, J., Samet, J.M., 1997. The sleep heart health study: design, rationale, and methods. *Sleep* 20, 1077–1085.

Raz, N., Rodrigue, K.M., 2006. Differential aging of the brain: patterns, cognitive correlates and modifiers. *Neurosci. Biobehav. Rev.* 30, 730–748.

- Rechtschaffen, A., Kales, A., 1968. A Manual Of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. U.S. Government Printing Office, Washington DC.
- Redline, S., Kirchner, H.L., Quan, S.F., Gottlieb, D.J., Kapur, V., Newman, A., 2004. The effects of age, sex, ethnicity, and sleep-disordered breathing on sleep architecture. *Arch. Intern. Med.* 164, 406–418.
- Redline, S., Sanders, M.H., Lind, B.K., Quan, S.F., Iber, C., Gottlieb, D.J., Bonekat, W.H., Rapoport, D.M., Smith, P.L., Kiley, J.P., 1998. Methods for obtaining and analyzing unattended polysomnography data for a multicenter study. *Sleep* 21, 759–767.
- Roehrs, T., Roth, T., 2010. Drug-related sleep stage changes: functional significance and clinical relevance. *Sleep Med. Clin.* 5, 559–570.
- Scullin, M.K., 2017. Do older adults need sleep? A review of neuroimaging, sleep, and aging studies. *Curr. Sleep Med. Rep.* 3, 204–214.
- Steffener, J., Habeck, C., O'Shea, D., Razlighi, Q., Bherer, L., Stern, Y., 2016. Differences between chronological and brain age are related to education and self-reported physical activity. *Neurobiol. Aging* 40, 138–144.
- Sun, H., Jia, J., Goparaju, B., Huang, G.-B., Sourina, O., Bianchi, M.T., Westover, M.B., 2017. Large-scale Automated sleep staging. *Sleep* 40.
- Tasali, E., Leproult, R., Ehrmann, D.A., Van Cauter, E., 2008. Slow-wave sleep and the risk of type 2 diabetes in humans. *Proc. Natl. Acad. Sci. U. S. A.* 105, 1044–1049.
- Ujma, P.P., Konrad, B.N., Gombos, F., Simor, P., Pótári, A., Genzel, L., Pawlowski, M., Steiger, A., Bódizs, R., Dresler, M., 2017. The sleep EEG spectrum is a sexually dimorphic marker of general intelligence. *Sci. Rep.* 7, 18070.
- Vanhooren, V., Dewaele, S., Libert, C., Engelborghs, S., De Deyn, P.P., Toussaint, O., Debacq-Chainiaux, F., Poulain, M., Glupczynski, Y., Franceschi, C., 2010. Serum N-glycan profile shift during human ageing. *Exp. Gerontol.* 45, 738–743.